About Synapsin-3
Synapsin-3 (SYN3) is a protein
from Homo sapiens identified by UniProt accession
O14994, 580 residues long.
MolForge cross-references it against 0 known binders and
88 disease associations.
Target properties
| Protein name | Synapsin-3 |
| UniProt accession | O14994 |
| Gene | SYN3 |
| Organism | Homo sapiens |
| Length | 580 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (88)
Diseases linked to this target (Open Targets).
- Sorsby fundus dystrophy · score 0.51
- FEV/FVC ratio · score 0.47
- Retinal dystrophy · score 0.39
- Generalized hypotonia · score 0.33
- Global developmental delay · score 0.33
- Cerebellar vermis atrophy · score 0.33
- Visual impairment · score 0.33
- Seizure · score 0.33
- chronic obstructive pulmonary disease · score 0.33
- Cerebral arteriovenous malformation · score 0.27
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-O14994-F1 | alphafold | PREDICTED | 72.55 | — |
Amino-acid sequence (580 residues)
MNFLRRRLSD SSFMANLPNG YMTDLQRPDS STSSPASPAM ERRHPQPLAA SFSSPGSSLF SSLSSAMKQA PQATSGLMEP PGPSTPIVQR PRILLVIDDA HTDWSKYFHG KKVNGEIEIR VEQAEFSELN LAAYVTGGCM VDMQVVRNGT KVVSRSFKPD FILVRQHAYS MALGEDYRSL VIGLQYGGLP AVNSLYSVYN FCSKPWVFSQ LIKIFHSLGP EKFPLVEQTF FPNHKPMVTA PHFPVVVKLG HAHAGMGKIK VENQLDFQDI TSVVAMAKTY ATTEAFIDSK YDIRIQKIGS NYKAYMRTSI SGNWKANTGS AMLEQVAMTE RYRLWVDSCS EMFGGLDICA VKAVHSKDGR DYIIEVMDSS MPLIGEHVEE DRQLMADLVV SKMSQLPMPG GTAPSPLRPW APQIKSAKSP GQAQLGPQLG QPQPRPPPQG GPRQAQSPQP QRSGSPSQQR LSPQGQQPLS PQSGSPQQQR SPGSPQLSRA SSGSSPNQAS KPGATLASQP RPPVQGRSTS QQGEESKKPA PPHPHLNKSQ SLTNSLSTSD TSQRGTPSED EAKAETIRNL RKSFASLFSD
Explore Synapsin-3 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets